Table 3.
Dosage for individual drugs for patients receiving a bDMARD
| Drug | Dosage | |||
|---|---|---|---|---|
| Standard | Under | Over | Total | |
| Etanercept (originator) | 1310 (94.4) | 71 (5.1) | 7 (0.5) | 1388 |
| Etanercept (SB4, biosimilar) | 457 (98.5) | 7 (1.5) | 0 (0) | 464 |
| Etanercept (GP2015, biosimilar) | 102 (98.1) | 2 (1.9) | 0 (0) | 104 |
| Infliximab (originator) | 107 (78.1) | 6 (4.4) | 24 (17.5) | 137 |
| Adalimumab (originator) | 1259 (98.9) | 5 (0.4) | 9 (0.7) | 1273 |
| Certolizumab (originator) | 710 (94.8) | 9 (1.2) | 30 (4.0) | 749 |
| Golimumab (originator) | 362 (97.3) | 5 (1.3) | 5 (1.3) | 372 |
| Abatacept s.c. (originator) | 292 (99.3) | 2 (0.7) | 0 (0) | 294 |
| Abatacept i.v. (originator) | 150 (81.5) | 30 (16.3) | 4 (2.2) | 185 |
| Rituximab (originator) | 581 (90.2) | 63 (9.8) | 0 (0) | 644 |
| Tocilizumab s.c. (originator) | 326 (94.8) | 8 (2.3) | 10 (2.9) | 344 |
| Tocilizumab i.v. (originator) | 682 (90.8) | 36 (4.8) | 33 (4.4) | 751 |
| Total | 6338 (94.5) | 245 (3.7) | 122 (1.8) | 6705 |
Data are presented as n (%). The available dosage information during the first 3 months of treatment for the drugs shown represents 6705 of 7200 patients receiving a biologic DMARD, i.e. 93.1% of those patients. In case of missing data, the dosage intended at baseline is considered. For tocilizumab and abatacept, s.c. and i.v. routes of administration are shown separately. One abatacept patient was not considered in this table due to an unknown route of administration.